Welcome to our dedicated page for Pharvaris news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris stock.
Pharvaris N.V. reports developments as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Its lead program, deucrictibant, is being developed in immediate-release capsule and extended-release tablet forms for on-demand and prophylactic treatment settings.
Recurring updates include clinical data from the RAPIDe and CHAPTER study programs, patient-reported outcome research, scientific publications, presentations at allergy and immunology meetings, financial results, strategic priorities, shareholder voting matters and capital-structure disclosures.
Pharvaris (Nasdaq: PHVS) reported new EAACI 2026 data on oral deucrictibant for hereditary angioedema (HAE). Phase 3 RAPIDe-3 showed median 1.28 hours to symptom relief and 11.95 hours to complete resolution versus over 12 and 48 hours with placebo, and a median 17.47 minutes to End of Progression™ versus 228.67 minutes.
In Phase 2 CHAPTER-1 long-term prophylaxis, attack rates fell by ~92% on average and about half of participants were attack-free. An integrated analysis in ~570 participants showed a favorable cardiovascular safety profile, and a validated kinin biomarker assay may help differentiate bradykinin-mediated angioedema.
Pharvaris (Nasdaq: PHVS) announced its annual general meeting of shareholders will be held on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).
Meeting documents, including the notice and agenda, are available in the website’s Investors > Events & Presentations section and on the SEC website.
Pharvaris (Nasdaq: PHVS) will present new clinical data on its oral bradykinin B2 receptor antagonist deucrictibant at the EAACI Annual Congress 2026 in Istanbul from June 12-15, 2026.
According to Pharvaris, one oral presentation and seven flash talk/poster sessions will cover Phase 3 RAPIDe-3 and Phase 2 CHAPTER-1 results in hereditary angioedema, cardiovascular safety, biomarker development, long-term prophylaxis, and patient-reported outcomes. Slides and posters will be posted on its investor website at the time of each presentation.
Pharvaris (Nasdaq: PHVS) reported first quarter 2026 results and a late-stage HAE pipeline update. Cash and cash equivalents were €247 million on March 31, 2026, excluding a subsequent $132.3 million underwritten offering that is expected to extend the cash runway into 2028.
Topline data from Phase 3 CHAPTER-3 of deucrictibant XR for prophylactic HAE treatment are expected in 3Q2026, and an NDA for deucrictibant IR for on-demand HAE treatment remains on track for 1H2026. Enrollment continues in the CHAPTER-4 extension and CREAATE Phase 3 AAE-C1INH study.
Pharvaris (Nasdaq: PHVS) closed an underwritten public offering of 4,455,863 ordinary shares, including full exercise of the underwriters’ option for 581,199 additional shares. Gross proceeds were approximately $132.3 million before fees and expenses. All shares were sold by Pharvaris under an effective SEC shelf registration.
Pharvaris (NASDAQ: PHVS) priced an underwritten offering of 3,874,664 ordinary shares at $29.68 per share, with gross proceeds expected to be approximately $115 million before underwriting discounts, commissions and expenses.
The underwriters have a 30-day option for an additional 581,199 shares. The offering is expected to close on or about May 11, 2026, subject to customary closing conditions.
Pharvaris (Nasdaq: PHVS) presented data at CIIC Spring 2026 showing that combined use of a 40 mg deucrictibant XR prophylactic tablet with one or two 20 mg IR capsules for breakthrough attacks is supported by calculated safety margins. A post-hoc CHAPTER-1 analysis showed comparable mean durations for icatibant-treated attacks across placebo and deucrictibant arms, offering initial evidence for the mechanism-on-mechanism approach. Pharvaris highlighted safety and early efficacy signals and said it will further explore combined prophylactic and on-demand deucrictibant use.
Pharvaris (Nasdaq: PHVS) reported Q4 and full-year 2025 results and provided a business update on deucrictibant clinical programs. Key milestones: CHAPTER-3 enrollment complete with topline data expected in 3Q2026, RAPIDe-3 pivotal success supports an on-track NDA submission in 1H2026, and cash of €292 million at year-end.
Company continues enrollment in CREAATE and long-term CHAPTER-4 extension while highlighting RAPIDe-3 median onset and resolution times versus placebo.
Pharvaris (Nasdaq: PHVS) announced publication of two Phase 2 trials in The Lancet Haematology showing deucrictibant, an oral bradykinin B2 receptor antagonist, had statistically significant efficacy and was well tolerated for both prophylaxis (CHAPTER-1) and on-demand treatment (RAPIDe-1) of hereditary angioedema (HAE) attacks.
The company said CHAPTER-1 showed reduced attack occurrence and improved quality of life, while RAPIDe-1 showed reduced attack severity and faster symptom relief; Phase 3 topline from CHAPTER-3 is expected in Q3 2026.
Pharvaris (Nasdaq: PHVS) published a peer-reviewed study validating patient-reported outcome (PRO) instruments for on-demand hereditary angioedema (HAE) treatment endpoints.
The non-interventional, mixed-methods study found PGI and AMRA tools reliable and sensitive, identified End of Progression™ as earliest meaningful endpoint, and aligned PGI-C "a little better" with AMRA-3 ≥20%, informing Phase 3 RAPIDe-3 endpoint hierarchy.